on January 22, 2009
Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print January 22, 2009, doi: 10.1161/ATVBAHA.108.179663
Published online before print January 22, 2009, doi: 10.1161/ATVBAHA.108.179663
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 26, 2008
Accepted on January 3, 2009
History of Discovery: Vascular Endothelial Growth Factor
Napoleone Ferrara *
From Genentech Inc, San Francisco, Calif.
* To whom correspondence should be addressed. E-mail: nf{at}gene.com.
Abstract—Vascular endothelial growth factor (VEGF, VEGF-A) is a major regulator of physiological and pathological angiogenesis. Several VEGF inhibitors have been approved by the FDA for the treatment of advanced cancer and neovascular age-related macular degeneration. This brief review provides a historic account of the challenges associated with the discovery of VEGF and the early steps in elucidating the role of this molecule in the regulation of angiogenesis.
This article has been cited by other articles:
 |
|
 |
|
  J. W. Holaday and B. A. Berkowitz Antiangiogenic Drugs: Insights into Drug Development from Endostatin, Avastin and Thalidomide Mol. Interv., August 1, 2009; 9(4): 157 - 166. [Full Text] [PDF]
|
|